NASDAQ:INFI - Infinity Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.25
  • Forecasted Upside: 386.11 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.08
▲ +0.05 (4.85%)

This chart shows the closing price for INFI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Infinity Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INFI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INFI

Analyst Price Target is $5.25
▲ +386.11% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Infinity Pharmaceuticals in the last 3 months. The average price target is $5.25, with a high forecast of $9.00 and a low forecast of $3.00. The average price target represents a 386.11% upside from the last price of $1.08.

This chart shows the closing price for INFI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Infinity Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2022Piper SandlerLower Price TargetOverweight$4.00 ➝ $3.00Low
3/31/2022Truist FinancialLower Price TargetBuy$12.00 ➝ $4.00High
3/29/2022Piper SandlerLower Price TargetOverweight$8.00 ➝ $4.00High
1/24/2022B. RileyLower Price Target$7.00 ➝ $5.00High
12/13/2021HC WainwrightReiterated RatingBuy$9.00High
10/18/2021HC WainwrightInitiated CoverageBuy$9.00High
8/2/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$6.00High
7/28/2021B. RileyLower Price TargetBuy$7.00 ➝ $4.00High
7/28/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$4.00 ➝ $14.00High
7/27/2021Piper SandlerReiterated RatingOverweight$7.00 ➝ $8.00High
7/7/2021B. RileyReiterated RatingBuy$7.00High
3/23/2021B. RileyLower Price TargetBuy$8.00 ➝ $7.00Low
3/18/2021Truist FinancialInitiated CoverageBuy$12.00High
3/17/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$2.00 ➝ $4.00High
2/25/2021Piper SandlerInitiated CoverageOverweight$7.00Medium
2/18/2021Piper SandlerInitiated CoverageOverweight$7.00 ➝ $7.00Low
2/12/2021B. RileyBoost Price TargetBuy$4.50 ➝ $8.00Low
2/11/2021OppenheimerBoost Price TargetOutperform$5.50 ➝ $9.00Low
2/5/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralMedium
12/11/2020B. RileyBoost Price TargetBuy$3.00 ➝ $4.50High
11/13/2020B. RileyBoost Price TargetBuy$2.50 ➝ $3.00High
7/31/2020OppenheimerReiterated RatingBuyHigh
5/18/2020B. RileyLower Price TargetBuy$3.50 ➝ $2.50Low
5/12/2020Wells Fargo & CompanyLower Price TargetEqual Weight$1.50 ➝ $1.00High
5/11/2020OppenheimerReiterated RatingBuy$3.00High
3/4/2020Wells Fargo & CompanyLower Price TargetEqual Weight$2.50 ➝ $1.50Medium
11/18/2019B. RileyInitiated CoverageBuy$3.50High
6/27/2019CIBCInitiated CoverageOutperform ➝ OutperformLow
6/27/2019OppenheimerInitiated CoverageOutperform$3.00Medium
1/7/2019UBS GroupReiterated RatingReduceHigh
1/4/2019B. RileyInitiated CoverageBuy ➝ Buy$3.00 ➝ $3.00High
11/12/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
11/12/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
10/12/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/14/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/13/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/14/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Infinity Pharmaceuticals logo
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.08
Low: $1.03
High: $1.14

50 Day Range

MA: $0.72
Low: $0.59
High: $1.08

52 Week Range

Now: $1.08
Low: $0.46
High: $3.89

Volume

1,438,873 shs

Average Volume

823,013 shs

Market Capitalization

$96.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Infinity Pharmaceuticals?

The following equities research analysts have issued research reports on Infinity Pharmaceuticals in the last twelve months: B. Riley, HC Wainwright, Piper Sandler, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for INFI.

What is the current price target for Infinity Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Infinity Pharmaceuticals in the last year. Their average twelve-month price target is $5.25, suggesting a possible upside of 386.1%. HC Wainwright has the highest price target set, predicting INFI will reach $9.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $3.00 for Infinity Pharmaceuticals in the next year.
View the latest price targets for INFI.

What is the current consensus analyst rating for Infinity Pharmaceuticals?

Infinity Pharmaceuticals currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INFI will outperform the market and that investors should add to their positions of Infinity Pharmaceuticals.
View the latest ratings for INFI.

What other companies compete with Infinity Pharmaceuticals?

How do I contact Infinity Pharmaceuticals' investor relations team?

Infinity Pharmaceuticals' physical mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company's listed phone number is (617) 453-1000 and its investor relations email address is [email protected] The official website for Infinity Pharmaceuticals is www.infi.com. Learn More about contacing Infinity Pharmaceuticals investor relations.